Sensor-augmented pump therapy lowers HbA 1c in suboptimally controlled Type1 diabetes; a randomized controlled trial

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1158-1167

  Hermanides, J ^a   Norgaard K ^b   Bruttomesso, D ^c   Mathieu, C ^d   Frid, A ^e   Dayan, C M ^f   Diem, P ^g   Fermon, C ^h   Wentholt, I M E ^a   Hoekstra, J B L ^a   Devries, J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g UNIVERSITY OF BERN   (Switzerland)

^h CENTRE HOSPITALIER DE ROUBAIX   (France)

Author keywords

Continuous blood glucose monitoring; Continuous subcutaneous insulin infusion; Randomized controlled trial; Type1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SENSOR; SENSOR AUGMENTED INSULIN PUMP; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; EUROPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960098673     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03256.x     Document Type: Article

References (24)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31: S12-S54.
3. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with Type1 and Type2 diabetes: normative values. Diabetes Care 2005; 28: 2361-2366.
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176.
5. Wentholt IM, Maran A, Masurel N, Heine RJ, Hoekstra JB, DeVries JH. Nocturnal hypoglycaemia in Type1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associations. Diabet Med 2007; 24: 527-532.
6. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25years: evidence base for the expanding use of insulin pump therapy in type1 diabetes. Diabetes Care 2002; 25: 593-598.
7. Wentholt IM, Hoekstra JB, DeVries JH. Continuous glucose monitors: the long-awaited watch dogs? Diabetes Technol Ther 2007; 9: 399-409.
8. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774.
9. Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951.
10. 1c. Diabetes Care 2004; 27: 2590-2596.
11. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type1 diabetes. N Engl J Med 2008; 359: 1464-1476.
12. Mastrototaro JJ, Cooper KW, Soundararajan G, Sanders JB, Shah RV. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study. Adv Ther 2006; 23: 725-732.
13. Hanaire H. Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop. Diabetes Metab 2006; 32: 534-538.
14. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of Type1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. J Am Med Assoc 2003; 290: 2159-2167.
15. Ware JEJP. SF-36 Health Survey Update. Spine 2000; 25: 3130-3139.
16. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE et al. Assessment of diabetes-related distress. Diabetes Care 1995; 18: 754-760.
17. Bradley C. The Diabetes Treatment Satisfaction Questionnaire:DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994: 111-132.
18. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
19. Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008; 10: 377-383.
20. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type1 diabetes: The RealTrend study. Diabetes Care 2009; 32: 2245-2250.
21. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N et al. Improved glycemic control in poorly controlled patients with Type1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730-2732.
22. Hermanides J, DeVries JH. Sense and nonsense in sensors. Diabetologia 2010; 53: 593-596.
23. O'Connell M, Donath S, O'Neal D, Colman PG, Ambler GR, Jones TW et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type1 diabetes: a randomised controlled trial. Diabetologia 2009; 52: 1250-1257.
24. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.